Corcept Therapeutics (CORT) Set to Announce Earnings on Wednesday

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of $0.27 per share for the quarter. Corcept Therapeutics has set its FY 2024 guidance at EPS.Investors interested in registering for the company's conference call can do so using this link.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings results on Monday, July 29th. The biotechnology company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.09. Corcept Therapeutics had a net margin of 21.93% and a return on equity of 23.66%. The company had revenue of $163.80 million for the quarter, compared to analysts' expectations of $155.14 million. During the same period last year, the firm posted $0.25 earnings per share. The business's quarterly revenue was up 39.1% compared to the same quarter last year. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Corcept Therapeutics Stock Down 1.7 %

Shares of CORT traded down $0.82 during trading hours on Thursday, reaching $47.24. The stock had a trading volume of 852,766 shares, compared to its average volume of 1,184,941. The company has a market cap of $4.92 billion, a P/E ratio of 44.80 and a beta of 0.46. Corcept Therapeutics has a 52 week low of $20.84 and a 52 week high of $50.07. The firm has a 50-day moving average of $40.53 and a 200 day moving average of $33.48.

Insider Buying and Selling at Corcept Therapeutics

In other news, insider Gary Charles Robb sold 3,101 shares of the firm's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $35.71, for a total value of $110,736.71. Following the completion of the transaction, the insider now owns 23,190 shares in the company, valued at $828,114.90. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Corcept Therapeutics news, insider William Guyer sold 10,000 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $38.67, for a total value of $386,700.00. Following the completion of the sale, the insider now owns 6,039 shares in the company, valued at $233,528.13. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gary Charles Robb sold 3,101 shares of the business's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $35.71, for a total transaction of $110,736.71. Following the transaction, the insider now owns 23,190 shares in the company, valued at $828,114.90. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,251 shares of company stock worth $1,365,292. Insiders own 20.50% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on CORT shares. HC Wainwright raised their price target on Corcept Therapeutics from $45.00 to $80.00 and gave the stock a "buy" rating in a research report on Friday, October 18th. Canaccord Genuity Group reiterated a "buy" rating and issued a $38.00 price target on shares of Corcept Therapeutics in a report on Tuesday, July 30th. Sandler O'Neill restated a "buy" rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Truist Financial upped their target price on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the stock a "buy" rating in a research note on Monday, September 30th. Finally, Piper Sandler increased their target price on Corcept Therapeutics from $38.00 to $67.00 and gave the stock an "overweight" rating in a report on Wednesday, September 18th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $65.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.